Compare PCRX & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | HDL |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2011 | 2024 |
| Metric | PCRX | HDL |
|---|---|---|
| Price | $26.23 | $17.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $32.86 | N/A |
| AVG Volume (30 Days) | ★ 723.2K | 2.3K |
| Earning Date | 11-06-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.47 | 0.04 |
| Revenue | $716,791,000.00 | ★ $820,865,000.00 |
| Revenue This Year | $6.24 | $11.19 |
| Revenue Next Year | $9.53 | $13.37 |
| P/E Ratio | ★ $55.78 | $438.76 |
| Revenue Growth | 3.14 | ★ 8.02 |
| 52 Week Low | $18.17 | $16.30 |
| 52 Week High | $27.64 | $30.00 |
| Indicator | PCRX | HDL |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 45.04 |
| Support Level | $25.17 | $17.00 |
| Resistance Level | $24.81 | $17.49 |
| Average True Range (ATR) | 0.96 | 0.27 |
| MACD | 0.26 | -0.03 |
| Stochastic Oscillator | 76.49 | 30.67 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.